Literature DB >> 90760

Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2.

J Stocks, G Holdsworth, D Galton.   

Abstract

Two men aged 48 and 35 years with severe hypertriglyceridaemia, glucose intolerance, and a secondary anaemia had more apolipoprotein C-III-2 and less apo C-III-1 on their triglyceride-rich lipoproteins (d less than 1.006) than did types IV or V lipaemic controls. Although the patients' abnormal lipoproteins seemed to produce normal activation of lipoprotein lipase, they did not serve as an efficient substrate for purified lipoprotein lipase. Adipose tissue of case 1 had considerable lipoprotein-lipase activity and the hypertriglyceridaemia responded to dietary therapy (carbohydrate 180 g, fat 80 g, protein 60 g per day, and no alcohol). The haemolytic anaemia improved, but the patient remained glucose intolerant. The abnormal content of apo C-III-2 on the triglyceride-rich lipoproteins, rendering them resistant to clearance by lipoprotein lipase, is believed to have contributed to the patients' severe hypertriglyceridaemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90760     DOI: 10.1016/s0140-6736(79)92068-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Haplotypes identified by DNA polymorphisms at the apolipoprotein A-1 and C-III loci and hypertriglyceridaemia. A study in a Japanese population.

Authors:  A Rees; J Stocks; H Paul; Y Ohuchi; D Galton
Journal:  Hum Genet       Date:  1986-02       Impact factor: 4.132

2.  Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

Authors:  Adriaan G Holleboom; Helen Karlsson; Ruei-Shiuan Lin; Thomas M Beres; Jeroen A Sierts; Daniel S Herman; Erik S G Stroes; Johannes M Aerts; John J P Kastelein; Mohammad M Motazacker; Geesje M Dallinga-Thie; Johannes H M Levels; Aeilko H Zwinderman; Jonathan G Seidman; Christine E Seidman; Stefan Ljunggren; Dirk J Lefeber; Eva Morava; Ron A Wevers; Timothy A Fritz; Lawrence A Tabak; Mats Lindahl; G Kees Hovingh; Jan Albert Kuivenhoven
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

3.  Apolipoprotein C-III can specifically bind to hepatic plasma membranes.

Authors:  D Z Fang; B W Liu
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

4.  Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout.

Authors:  D G Macfarlane; C A Midwinter; P A Dieppe; C H Bolton; M Hartog
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

5.  Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Authors:  N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

6.  Familial disorders of plasma apolipoproteins.

Authors:  C R Sirtori; G Franceschini
Journal:  Klin Wochenschr       Date:  1985-06-03

7.  An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.

Authors:  G Holdsworth; J Stocks; P Dodson; D J Galton
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Authors:  B Staels; N Vu-Dac; V A Kosykh; R Saladin; J C Fruchart; J Dallongeville; J Auwerx
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.